Evicenter
MarkdownMedical informationP&T meetings
Cretostimogene grenadenorepvec (CG0070)

BCG-unresponsive high-risk non-muscle-invasive bladder cancer

Manufacturer
CG Oncology
Launch
Not announced
Last updated
161 sources

Executive summary

Burden of BCG-unresponsive high-risk non-muscle-invasive bladder cancer

3 evidence topics · 30 sources

Summary: definition and epidemiology

The 2026 European Association of Urology guidelines define BCG-unresponsive tumours as all BCG-refractory tumours and high-grade Ta/T1 recurrence within 6 months or carcinoma in situ (CIS) within 12 months of completion of adequate BCG exposure, where adequate BCG is at least five of six doses of an initial induction course plus at least two of six doses of a second induction course or two of three doses of maintenance therapy. FDA guidance also includes T1 high-grade disease at the first evaluation following induction BCG and states that patients with BCG-unresponsive NMIBC “are unlikely to benefit from further therapy with BCG”.

  • Bladder cancer in the United States: the American Cancer Society estimates 84,530 new cases and 17,870 deaths in 2026, with in situ disease included in the case estimate; SEER reports 17.9 new cases per 100,000 per year, a median age at diagnosis of 73, and an estimated 763,031 people living with bladder cancer in 2023. A second source reports a prevalence of 744,039 individuals in 2022.
  • Share diagnosed as NMIBC: 74% and approximately three-quarters in two 2026 articles, 73.1% in a SEER-Medicare analysis cited by a 2026 budget impact analysis of nadofaragene firadenovec, and approximately 70% in the 2020 ICER review.
  • BCG failure: three sources report that initial BCG fails in approximately 40% of patients over a 2-year span, that high-risk NMIBC recurs after adequate BCG in approximately 40%, and that more than 40% of patients with high-risk NMIBC do not respond to initial BCG.
  • The eligible-population estimates apply stage and BCG-response proportions to bladder cancer figures. The 2020 ICER review assumed approximately 38% BCG non-responders and, starting from a SEER prevalence of 712,614 people in 2017, estimated 70,135 eligible individuals, 51,180 (73%) with Ta and T1 disease and 18,956 (27%) with CIS. The 2026 budget impact analysis cites a SEER bladder cancer prevalence of 0.0634% and incidence of 0.0244% and SEER-Medicare proportions of 42.3% high-risk among NMIBC, 56.5% of high-risk NMIBC treated with BCG, and 30% of those unresponsive, and estimate that a health plan with one million lives has 5.5, 4.9, and 4.5 adults with high-risk BCG-unresponsive NMIBC with CIS ± Ta/T1 eligible for nadofaragene firadenovec in Years 1 to 3, or 33.2, 29.7, and 27.5 when Ta/T1-only disease is added.
  • Real-world classification: in a cohort of 26,876 participants with NMIBC, 3,134 of 5,271 participants (59.3%) with CIS-containing tumors and sufficient follow-up recurred within 24 months, of whom 530 (16.9%) were BCG unresponsive and 2,604 (83.1%) BCG exposed, and 24.9% (4,951 of 19,889) of participants across all risk groups received maintenance BCG. In a retrospective cohort at Moffitt Cancer Center (1988 to 2024), 470 of 1,076 participants with BCG-treated high-grade NMIBC were classifiable, of whom 225 (47.9%) were BCG-unresponsive. A 2026 article reports that a substantial proportion of patients cannot be classified because the exposure-based and time-dependent conditions of regulatory definitions are not met in routine practice.
Summary: natural history, survival, and treatment morbidity
  • Bladder cancer is the tenth leading cause of cancer death in the United States, with a death rate of 4.1 per 100,000 per year in SEER data. The American Cancer Society reports five-year relative survival of 79% overall and 98% for in situ disease.
  • In a SEER-Medicare analysis of 7,410 participants with high-risk bladder cancer, 2,897 (39.1%) had a recurrence without progression and 2,449 (33.0%) progressed, of whom 981 died of bladder cancer; 10-year recurrence, progression, and bladder cancer-related mortality rates were 74.3%, 33.3%, and 12.3%.
  • In one cohort, progression-free survival time was 18 months for 17 BCG-refractory participants and 52 months for 15 BCG-relapsing participants (P = 0.001); 8 (47%) and 3 (20%) had died. Among 85 participants with T1 recurrence treated initially with repeat transurethral resection and intravesical BCG, the 5-year cumulative incidence of progression to T2 disease was 71% and of death from disease 48%; in a cohort of 129 participants with recurrent T1, of whom 65 underwent immediate radical cystectomy, the corresponding figures were 28% and 31%.
  • Among adults with high-risk BCG-unresponsive NMIBC, 92.6% and 81.2% were alive at Years 2 and 3 in a SEER-Medicare analysis.
  • In a cohort of 578 participants with BCG-unresponsive NMIBC (28% upfront radical cystectomy, 72% bladder-sparing therapy; median follow-up 50 months), metastasis-free, cancer-specific, and overall survival did not differ significantly between groups. With bladder-sparing therapy, high-grade recurrence rates were 37% and 52% and progression to MIBC 7% and 13% at 12 and 24 months.
  • In a cohort of 570 participants previously treated with induction BCG (371 selected bladder-sparing therapy, 199 radical cystectomy), cancer-specific survival was 99% and 96%, and 12-month progression-free survival was 92% and 73%, respectively, with 22% of participants undergoing radical cystectomy having pathology demonstrating MIBC. Within 12 months, 27 (8.1%) participants in the bladder-sparing arm underwent radical cystectomy. Adverse events occurred in 62% after radical cystectomy and 38% with bladder-sparing therapy; after radical cystectomy, 57 (30%) participants were readmitted and five (2.5%) died within 90 days.
  • Long-term morbidity of urinary diversion: in one series, 643 participants (60.8%) had 1,453 complications attributable to the diversion, and in a cohort of 563 participants who underwent cystectomy with urinary diversion, mean glomerular filtration rate losses at 5 years were 17% and 14% of baseline in the two diversion groups.
Summary: humanistic and economic burden
  • Health-related quality of life: in the same cohort of 570 participants, the primary outcome, EORTC QLQ-C30 physical function at 12 months, did not differ between bladder-sparing therapy and radical cystectomy (mean 85.4 and 86.2; P = .22), after being worse with radical cystectomy at 3 months. At 12 months, emotional function, cognitive function, global health, anxiety, and depression were better with radical cystectomy, and bowel and sexual summary scores were worse. In another study, NMIBC survivors had lower quality of life than the general population, especially in fatigue, physical and role functioning, and mental health. Across 17 studies totaling 20,045 participants, withdrawal rates reached up to 90% in intensive instillation schedules.
  • Utilities: in time trade-off interviews with 202 members of the UK general public, mean utilities were 0.781 for no high-grade recurrence, 0.586 for high-grade recurrence, 0.288 for the first year after cystectomy, 0.572 for more than 1 year after cystectomy, and 0.283 for metastatic disease.
  • Preferences and treatment burden: among 206 respondents with self-reported NMIBC in a discrete-choice experiment survey, most (>70%) preferred bladder-sparing treatments over radical cystectomy except when comparing repeated BCG with radical cystectomy. Among 233 respondents to a survey on intravesical therapy, 61 (26%) reported that receiving bladder instillations adversely affected their regular daily activities, 55% (126/231) traveled more than 30 minutes to treatment, 56% (128/232) brought caregivers, and 36% (82/230) missed work.
  • Costs after BCG: among 986 participants aged 65 years or older with high-grade NMIBC who received adequate BCG induction (SEER-Medicare, diagnosed 2008 to 2015), 257 (26.1%) progressed; mean total annualized costs per patient after BCG were $39,102 overall, $65,668 with progression, and $29,780 without. Among 412 participants with high-risk NMIBC treated with BCG in Veterans Affairs centers, median costs (2019 USD) were $29,459 at 1 year, $55,267 at 2 years, and $117,361 at 5 years, and median 5-year costs were $232,729 with progressive disease and $94,879 without.
  • Costs of radical cystectomy and progression: median per-patient costs for 839 participants undergoing radical cystectomy were $70,671 at 90 days and $211,671 by 5 years. A Markov model estimated 5-year cumulative costs of $366,143 for high-risk NMIBC, with progression to muscle-invasive disease contributing 92% of the cost. Population changes are projected to increase bladder cancer care costs by 45% from 2015 through 2030, against an average of 39% across cancer sites.
  • Financial burden on patients and families: in the cohort of 570 participants, those in the bladder-sparing arm reported higher financial toxicity at 12 months than those in the radical cystectomy arm. Among 100 surveyed participants with NMIBC, the median COST score was 23, 61% reported at least mild financial toxicity, and 21% moderate financial toxicity. One article reports a roughly 60% retirement rate after bladder cancer diagnosis, a 22% unemployment rate among previously full-time workers, and surveillance accounting for more than half of the costs of the disease.